Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Inquiring,
Two words for you and the cabal; Keyoumars Ashkan!; ). Best wishes.
Inquirig,
We all know you are “trying to help”. Of course we all know you are not trying to help longs but rather shorts that need to close out their positions before news; ). No help from me with that!; ). Best wishes.
learningcurve 2020,
That protection advice was given at an ASM a while back when talking about ways to help prevent shorting and protect against naked shorting. Cash accounts and out of street name were two ways mentioned. Spoofing still works around this as does fear mongering like May 10th 2022 with anyone not sure of their investment. This all works hand in hand with the fact that others are trying to bluff them out of their expected eventual win. Best wishes.
John Bull,
So sorry for your loss that is coming. Now you have been warned!; ). Best wishes.
momentum2play,
Whatever works to retain the most value for shareholders is likely what she is moving towards and I agree that she has options beyond traditional thinking; ). Best wishes.
tryn2,
Just one more thing the bears don’t want to mention because that is additional leverage against any low ball offers to partner or other. NWBO has more friends that will pitch in at the right time than many realize and some very skilled folks might be very well pleased to ditch a big pharma acting poorly or in bad faith to move something like this forward on the ground floor. Best wishes.
manibiotech,
The journal article will attract a few more eyes and interest. Not until NWBO proves they are worth what they are asking with expected revenues and ability to move forward rapidly or big pharma is ready to partner with approval and automated manufacturing in place will the price rise accordingly. Until that time checkpoint inhibitor sales will continue to climb without the need to offer deference to the DCVax platform. When the investment community realizes that big pharma will be forced into deference then the tables turn. Big pharma will try to keep this from happening by timing their agreement(s). Linda has her timing involved too so it’s likely that the longer it takes for an agreement, unless already agreed to in principle at a certain milestone point, the more likely the agreement will be for bigger numbers. Seems likely there is a milestone trigger moment but Linda does have options ; ). Best wishes.
jesster64,
Not anywhere close to realistic. If you don’t think that NWBO will have at least 1,000 patients treated within 1 year of approval and at least $150,000,000 in revenue with current infrastructure creating a profit then you are not thinking things through. No one is going to be blocking reimbursement of this breakthrough treatment once Edens is validated. Best wishes.
tryn2,
The majority of big shareholders understand what they hold and will vote with Linda with their shares. The traders and those needing to cash out will be gobbled up by competing interests some of which will hold long when Linda’s plan gets fully revealed so no real good chance to wrest control from Linda now seeing where NWBO is at and the leverage they have with their products as much as some would like to try and convince otherwise ; ). Best wishes.
exwannabe,
Lots wrong with all of this but I’ll focus on tissue agnostic designation about which the proteomics study done by NWBO clearly refuted your claim. Individual critical targets were identified that are common to many cancers, viruses and other so “all” also includes specifics which are commonly known targets as well as some previously unknown. Best wishes.
iclight,
Maybe direct interest over any extended period of time would be counterproductive to the end goal of sidelining or buying as cheap as possible don’t you think or didn’t you think about that?; ). Too much light might blind a few on this board perhaps?; ). Can’t wait for discovery. Best wishes.
ilovetech,
The judge’s ruling on the spoofing case regarding motion to dismiss and the m journal article are the two most likely news items in the next 60 days in my opinion. I don’t believe partnership or trials will be announced until full Flaskworks validation. ASM announcement could be made if likely to coincide with some other news. Likely waiting for better positioning with regard to that news and I am only guessing that March would be a good time for an update and ASM based on being 80 days in from MAA review at which point the time remaining for review can be clarified to some extent perhaps. Best wishes.
exwannabe,
Maybe big pharma is so far behind all the “little” tweaks that make the DCVax platform special that they basically are conceding they have no way to catch up. Maybe their quicker efforts would just result in inferior products and money burned for no reason. Team NWBO has the experts with regard to proper DC activation/maturation and all the little tweaks add up. Trying to buy enough shares to gain control from retail longs is their last best option which is why crushing the price down so that they can gain a lower entry point from those so inclined to sell their shares on the cheap makes it all worth it for them. That is unless they get caught ; ). Best wishes.
tryn2,
Let’s just say that there are lots of very intelligent highly motivated folks who want to create a pathway to a cure and many of the innovators are not connected directly to big pharma. Best wishes.
Tom33777,
I think you are thinking of Autolomous and Dr. Mark Lowdell. He is also connected to INMune bio which is doing very well and was part of the picture with Linda Powers shared on this board years ago when Kristyn Powers’ dad was treated with L after a third non recommended surgery that left a significant amount of tumor behind but is still alive today about 10 years later.
These connections are not much talked about anymore but there is pathway forward for NWBO that many have not considered and it does not necessarily include an early buyout. Best wishes.
Inquirig,
I was looking for and led to a big winner early on with Celgene and now NWBO. I know you have the potential to be as well. Potential often takes time to be revealed.
Funny how the San Francisco 49ers starting quarterback was the last person taken in the NFL draft last year and now is in the Super Bowl. So close to never even getting a look by “the experts” and yet here he is on the world stage already having proved all the doubters wrong. NWBO is up next. When will it be your turn?; ). Best wishes.
georgebailey,
This is why NWBO really is in the driver’s seat except for cash which will come. Many investors have been conditioned not to see this but you are now beginning to which is part of the learning curve for all investors. If many on this board don’t have it figured out yet then how do you think other investors are looking at this recent news.
This Edens update is HUGE news but many simply do not understand how to interpret it. Now when they get the approval and the demand for treatment begins to be filled creating revenues then big pharma, the banks and other venture capitalists will all understand what this means and have planned or will plan to come to terms. Investors right now have the jump on all of this but many do not realize this yet. What’s the old mantra? Get the sales and everything else works its way out right?
The issue is that big pharma has recognized the threat and the opportunity for a long time but now they must deal with Linda and NWBO shareholders who support her on her terms. In the mean time they have been making lots of money on their checkpoint inhibitors and other without making any concessions that their future depends on the DCVax platform. Ever wonder why she has been attacked so much and why so much noise on the message boards? As the Danish Dude has often said “Know what you hold”. Best wishes.
Sojourner55,
You dropped in at a great time for longs to get a good look at what’s going on in the charts. Blessings and best wishes.
georgebailey,
Looking at this again, it does seem that the full scale up, not current is 1000 patients per month with artisan. Switching to Edens provides a 12x boost to this when fully scaled because 1 per clean room turns into 12 per clean room. That means a potential of about 144,000 patients treated per year at full scale with no artisan units retained with the whole campus fully developed. Full development also includes space for other businesses. This allows for 3-4 year rapid development plus certification as needed to achieve full buildout which is when I expect tissue agnostic designation to more fully kick into actual demand. Remember, Charles River Labs and Astra Zeneca are right near by and the UK promoted independent cell therapy capacity years ago which is now in place as well. Once Direct and tissue agnostic designations are fully factored in 144,000 patients will be a drop in the bucket of demand. Remember too that Linda Powers has been lobbying the “sameness” of L and Direct for years. That lobbying will continue full force and with more proof after L is approved as the cell activation and maturation process begins to be accepted as “the same process” only in different settings and stages. Best wishes.
sentiment_stocks,
Regression would be great in inoperable tumors especially if Direct could be brought in to finish off the tumor once space is created. Best wishes.
KIPK,
The science says checkpoint inhibitors given before L increase the odds of long term survival so a combo is likely in my opinion IF L is going to be utilized. There is also the very rare experimental opportunity for Direct to be utilized on the recommendation of a clinician for compassionate use and the company being willing to agree to supply with regulator clearance. Generally that happens with a treatment in a Phase 3 trial but with the safety record established from the Phase 1 first in man trial there might be an outside chance. I admittedly don’t know all the special rules and stipulations that would allow or prevent this. Best wishes.
Inquirig,
That blessing will come with the ability to bless others in a big way soon when the world wakes up one day to the reality that a new day in cancer treatment has dawned. I expect that day will not be unexpected by you and others posting negative comments about this platform nor will your absence be soon after ; ). Best wishes.
Springbok80,
ALL connections to NWBO are likely being monitored very closely at this point. The other issue is that those involved with NWBO can obviously see the potential for a major change ahead that they can benefit from more by being a part of instead of working against. Best wishes.
biosectinvestor,
Remember that L is limited by the number of antigens in just the tumor removed and needs help often times to control any remaining tumor which is made more difficult by unmethylated status microenvironment and micro metastis. Direct can be injected in multiple tumors but this wasn’t done in Phase 1. It also modifies the tumor environment by signaling which must remain constant/continuous to be the most effective. This can happen one of at least two ways. Proper interval between treatments or sufficient initial immune response that creates a steady influx of new uncompromised DCs from the patients own production of them which then continue to control the tumor environment by activation and maturation there. Every patient situation is different which is why treatment needs to be personalized but also consistent and continuous with proper spacing which treatment induced pseudo progression and trial protocols for first in man designation prevented in the Phase 1.
By the way, our grapefruit juice guy has become mighty quiet recently but the noise on the boards has increased. Seems like an inverse correlation to certain success has formed; ). Best wishes.
RuleofK,
Thanks. That is a different site and may have used the initial report picture. The site Lykiri posted changed the picture. Best wishes.
hyperopia,
The good thing is that this is all being done before Direct is fully validated because once that happens full scale global manufacturing must be in place due to expected immediate demand. L and Edens are paving the way for all product manufacturing and release issues that Direct would face too.
There is still the issue of world wide leukopheresis center footprint need which needs to expand significantly to meet expected demand. The patents for L and Direct allow for healthy compatible donors so there will be strong demand for heathy donors to provide leuk material at some point which will also expand the number of patients able to be treated who were kept out due to failed leuk attempts. Best wishes.
georgebailey,
That’s good, real good as a start because I believe that off label demand and use will be strong whether from trials or medical tourism. I have no doubt that Sawston will scale up rapidly and that those charged with getting the GMP components in sufficient supply to make them will figure that one out if still a problem to some extent. I certainly think Corning or other will be able to scale production up quickly especially Corning as they are familiar with what is required and did some of the early work in development. Thanks for sharing. Best wishes.
Lykiri,
At 9:35 EST the picture was swapped out/updated for a picture of the royal family; ). Best wishes.
georgebailey,
The question may be better asked about who might be building vaccine capacity and looking to finish them out maybe with C grade clean room standards and why ; ). Best wishes.
Bright Boy,
With digitization I don’t think they will need 12 people to watch 12 machines but rather at least one constantly ready to intervene and a backup to intervene when the other is working to remedy any issue on the batch that a warning may have come from. The need for personnel per batch has been greatly reduced in my opinion. Best wishes.
Gary,
Right to try was gutted before being allowed to pass as window dressing. It’s the same kind of folks in government that are influenced by the likes of Citadel and big pharma that did this to help maintain the status quo but make it look like they did something productive for the people who wanted more access to treatments like DCVax. They place the blame on the companies that choose not to participate when not doing so precisely for the protection of their IP from big pharma, at least some of whom may want to see them go bankrupt or at least be able to buy the IP out dirt cheap. Best wishes.
aperture007,
And we longs on ihub know this and many others do not. How valuable is that?; ). I mean especially if the stock is shortly to be viewed as worth 10-20x then climbing and we are still in the pennies. So what is one to do when they see a pearl of great price vs common or a Stradivarius violin priced the same as middle school used rental?; ). Best wishes.
wimike,
DOB is much more likely “date of batch” because of keeping everything confidential and 3 year limit granted for cryo preservation. Best wishes.
Inquirig,
You painted the board with predictions that this stock is going to zero ($) but now you hope it holds at $.40. Is your prediction about going to zero a lie or your hope that it holds $.40 a lie. Remember, you said you would retract any lies pointed out to you. So which one or even both would you like to retract?; ). Best wishes.
Lykiri,
I believe many have underestimated the influence of Dr. Keyoumars Ashkan and the amount of awareness about DCVax in the UK. Best wishes.
Sojourner55,
Looking good!; ). When looking at the lifetime chart and the upper trend base line the price should reach $12+ quickly with the right kind of news and awareness that this is the future caused by it. That will make a few folks happy but I’ll gladly be waiting for further news and awareness beyond that. Best wishes.
sentiment_stocks,
Do you remember those clown punching bags that were weighted on the bottom so that they kept returning to an upright position after being punched. No one getting hurt but kept us entertained and could be used to wear us out a little and let off some steam too. Hmmm. Wonder how that might apply here ; ). Best wishes.
sentiment_stocks,
An early signal that the push will be in the other direction soon methinks; ). Best wishes.
hyperopia,
Great post! As implied, I had hoped that due to delays that automation would be part of the MAA. What I originally believed is that the MAA application would not be submitted until Edens was essentially in the last stages of moving towards approval and that a BLA submission would be timed to coincide with the need to have manufacturing validated by about one month before a decision by FDA for approval of L with the new closed system process included. Looking forward to how it all plays out. Best wishes.
Sojourner55,
Always a pleasure to see you chime in. Longs who were looking to add a few more shares certainly had the chance to benefit from your skills. Can’t wait for the real fireworks to begin later this year. Best wishes.